The Korean Journal of Gastroenterology (대한소화기학회지)

The Korean Society of Gastroenterology (대한소화기학회)
권호 표지
DOI QR코드

DOI QR Code

Gastroesophageal Reflux Disease

위식도역류질환

  • Park, Chan Hyuk (Department of Internal Medicine, Hanyang University College of Medicine) ;
  • Lee, Sang Kil (Department of Internal Medicine, Yonsei University College of Medicine)
  • 박찬혁 (한양대학교 의과대학 내과학교실) ;
  • 이상길 (연세대학교 의과대학 내과학교실)
  • Received : 2018.12.28
  • Accepted : 2019.02.07
  • Published : 2019.02.25
⟨ Previous Next ⟩

Abstract

Gastroesophageal reflux disease (GERD) is a condition that develops when reflux of stomach contents causes troublesome symptoms and/or complications. The prevalence of GERD is increasing worldwide and in Asia-Pacific. The latest Korean guidelines for GERD were published in 2012, and several international guidelines and consensus statements for the management of GERD have also been recently published. Here, we review these guidelines and consensus statements in order to provide a better understanding of the diagnosis and treatment of GERD.

Keywords

References

  1. Jung H, Hong SJ, Jo YJ, et al. Updated guidelines 2012 for gastroesophageal reflux disease. Korean J Gastroenterol 2012;60:195-218. https://doi.org/10.4166/kjg.2012.60.4.195
  2. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014;63:871-880. https://doi.org/10.1136/gutjnl-2012-304269
  3. Fock KM, Talley N, Goh KL, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus. Gut 2016;65:1402-1415. https://doi.org/10.1136/gutjnl-2016-311715
  4. Kim N, Lee SW, Cho SI, et al. The prevalence of and risk factors for erosive oesophagitis and non-erosive reflux disease: a nationwide multicentre prospective study in Korea. Aliment Pharmacol Ther 2008;27:173-185. https://doi.org/10.1111/j.1365-2036.2007.03561.x
  5. DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190-200. https://doi.org/10.1111/j.1572-0241.2005.41217.x
  6. Hirano I, Richter JE, Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007;102:668-685. https://doi.org/10.1111/j.1572-0241.2006.00936.x
  7. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American gastroenterological association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1383-1391, 1391.e1-e5. https://doi.org/10.1053/j.gastro.2008.08.045
  8. Fock KM, Talley NJ, Fass R, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol 2008;23:8-22. https://doi.org/10.1111/j.1440-1746.2007.05249.x
  9. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308-328; quiz 329. https://doi.org/10.1038/ajg.2012.444
  10. Fuchs KH, Babic B, Breithaupt W, et al. EAES recommendations for the management of gastroesophageal reflux disease. Surg Endosc 2014;28:1753-1773. https://doi.org/10.1007/s00464-014-3431-z
  11. Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol 2016;51:751-767. https://doi.org/10.1007/s00535-016-1227-8
  12. Hunt R, Armstrong D, Katelaris P, et al. World gastroenterology organisation global guidelines: GERD global perspective on gastroesophageal reflux disease. J Clin Gastroenterol 2017;51:467-478. https://doi.org/10.1097/MCG.0000000000000854
  13. Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the lyon consensus. Gut 2018;67:1351-1362. https://doi.org/10.1136/gutjnl-2017-314722
  14. Cho YK, Kim GH, Kim JH, et al. Diagnosis of gastroesophageal reflux disease: a systematic review. Korean J Gastroenterol 2010;55:279-295. https://doi.org/10.4166/kjg.2010.55.5.279
  15. Lee JH, Cho YK, Jeon SW, et al. Guidelines for the treatment of gastroesophageal reflux disease. Korean J Gastroenterol 2011;57:57-66. https://doi.org/10.4166/kjg.2011.57.2.57
  16. Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Esophageal disorders. Gastroenterology 2016;150:1368-1379. https://doi.org/10.1053/j.gastro.2016.02.012
  17. Cho HS, Shin IS, Oh MK, et al. A strategy for dissemination and implementation of clinical practice guidelines in Korea. National Evidence-based Healthcare Collaborating Agency Research Report 2014;4:1-213.
  18. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-1920; quiz 1943. https://doi.org/10.1111/j.1572-0241.2006.00630.x
  19. Savarino E, Bredenoord AJ, Fox M, et al. Expert consensus document: advances in the physiological assessment and diagnosis of GERD. Nat Rev Gastroenterol Hepatol 2017;14:665-676. https://doi.org/10.1038/nrgastro.2017.130
  20. Farmer AD, Ruffle JK, Aziz Q. The role of esophageal hypersensitivity in functional esophageal disorders. J Clin Gastroenterol 2017;51:91-99. https://doi.org/10.1097/MCG.0000000000000757
  21. Woodland P, Al-Zinaty M, Yazaki E, Sifrim D. In vivo evaluation of acid-induced changes in oesophageal mucosa integrity and sensitivity in non-erosive reflux disease. Gut 2013;62:1256-1261. https://doi.org/10.1136/gutjnl-2012-302645
  22. Weijenborg PW, Smout AJ, Verseijden C, et al. Hypersensitivity to acid is associated with impaired esophageal mucosal integrity in patients with gastroesophageal reflux disease with and without esophagitis. Am J Physiol Gastrointest Liver Physiol 2014;307:G323-G329. https://doi.org/10.1152/ajpgi.00345.2013
  23. Weijenborg PW, Smout AJ, Bredenoord AJ. Esophageal acid sensitivity and mucosal integrity in patients with functional heartburn. Neurogastroenterol Motil 2016;28:1649-1654. https://doi.org/10.1111/nmo.12864
  24. Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2003;2:132-139. https://doi.org/10.1038/nrd1010
  25. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122:625-632. https://doi.org/10.1053/gast.2002.31876
  26. Rohof WO, Bennink RJ, Smout AJ, Thomas E, Boeckxstaens GE. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2013;11:1585-1591; quiz e90. https://doi.org/10.1016/j.cgh.2013.04.046
  27. Manabe N, Haruma K, Ito M, et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus 2012;25:373-380. https://doi.org/10.1111/j.1442-2050.2011.01276.x
  28. Mendlein J, Sachs G. Interaction of a K(+)-competitive inhibitor, a substituted imidazo[1,2a] pyridine, with the phospho- and dephosphoenzyme forms of $H^{+}$, K(+)-ATPase. J Biol Chem 1990;265:5030-5036. https://doi.org/10.1016/S0021-9258(19)34079-7
  29. Kirchhoff P, Andersson K, Socrates T, Sidani S, Kosiek O, Geibel JP. Characteristics of the $K^{+}$-competitive $H^{+}$,$K^{+}$-ATPase inhibitor AZD0865 in isolated rat gastric glands. Am J Physiol Gastrointest Liver Physiol 2006;291:G838-G843. https://doi.org/10.1152/ajpgi.00120.2006
  30. Simon WA, Herrmann M, Klein T, et al. Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther 2007;321:866-874. https://doi.org/10.1124/jpet.107.120428
  31. Berg AL, Bottcher G, Andersson K, et al. Early stellate cell activation and veno-occlusive-disease (VOD)-like hepatotoxicity in dogs treated with AR-H047108, an imidazopyridine proton pump inhibitor. Toxicol Pathol 2008;36:727-737. https://doi.org/10.1177/0192623308320802
  32. Akazawa Y, Fukuda D, Fukuda Y. Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence. Therap Adv Gastroenterol 2016;9:845-852. https://doi.org/10.1177/1756283X16668093
  33. Han KS, Kim YG, Yoo JK, Lee JW, Lee MG. Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats. Biopharm Drug Dispos 1998;19:493-500. https://doi.org/10.1002/(SICI)1099-081X(1998110)19:8<493::AID-BDD129>3.0.CO;2-Z
  34. Kim HK, Park SH, Cheung DY, et al. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. J Gastroenterol Hepatol 2010;25:1618-1625. https://doi.org/10.1111/j.1440-1746.2010.06408.x
  35. Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric $H^{+}$, $K^{+}$ -ATPase. Aliment Pharmacol Ther 2015;42:1315-1326. https://doi.org/10.1111/apt.13414
  36. Takahashi N, Take Y. Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility. J Pharmacol Exp Ther 2018;364:275-286. https://doi.org/10.1124/jpet.117.244202
  37. Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 2016;43:240-251. https://doi.org/10.1111/apt.13461
  38. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-1810. https://doi.org/10.1053/gast.1997.v112.pm9178669

Cited by

  1. Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole vol.15, 2019, https://doi.org/10.2147/dddt.s341271
  2. 기능성 위장관 질환의 한의학적 치료 연구전략 수립을 위한 연구 동향 분석 vol.29, pp.1, 2021, https://doi.org/10.14374/hfs.2021.29.1.57